A Study of Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma (PRIDE).
Latest Information Update: 09 Dec 2022
At a glance
- Drugs Daratumumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRIDE
- 24 Oct 2022 Planned initiation date changed from 1 Aug 2021 to 1 Oct 2022.
- 24 Oct 2022 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
- 24 Oct 2022 Status changed from not yet recruiting to recruiting.